

| Study or Subgroup | TENS | | | Placebo | | | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------------------|-------|-------|-------|---------|-------|-------|--|--|
| | Mean | SD | Total | Mean | SD | Total | | |
| 7.10.1 Acute Pain | | | | | | | | |
| Cipriano, et al., 2014 | 10 | 5 | 20 | 80 | 30 | 18 | 0.9% | -3.27 [-4.28, -2.27] |
| Mora, et al., 2006 | 33.3 | 16 | 39 | 82.6 | 14.3 | 34 | 1.1% | -3.20 [-3.91, -2.50] |
| Bertalanffy, et al., 2005 | 49 | 8 | 30 | 77 | 11 | 33 | 1.1% | -2.85 [-3.57, -2.14] |
| Tokuda, et al., 2014 | 5.9 | 6.5 | 16 | 23.8 | 5.9 | 16 | 0.9% | -2.81 [-3.82, -1.80] |
| Shahroei, et al., 2017 | 49 | 25 | 30 | 97 | 5.9 | 30 | 1.1% | -2.61 [-3.31, -1.91] |
| Ahmed, et al., 2010 | 49.3 | 7 | 30 | 66.1 | 6.9 | 30 | 1.1% | -2.39 [-3.06, -1.71] |
| Barker, et al., 2006 | 32.4 | 18 | 29 | 66.2 | 11.2 | 33 | 1.1% | -2.26 [-2.91, -1.61] |
| Lang, et al., 2007 | 59 | 6 | 30 | 79 | 11 | 33 | 1.1% | -2.20 [-2.83, -1.57] |
| Desantana, et al., 2008 | 9 | 10.7 | 20 | 48 | 22.7 | 20 | 1.0% | -2.15 [-2.95, -1.36] |
| Kim, et al., 2012 | 19 | 12 | 50 | 48 | 15 | 50 | 1.2% | -2.12 [-2.61, -1.63] |
| Baez-Suarez, et al., 2018 | 62 | 14 | 21 | 83 | 12 | 21 | 1.1% | -1.58 [-2.28, -0.88] |
| Desantana, et al., 2009 | 43 | 15.3 | 23 | 66.5 | 14.7 | 21 | 1.1% | -1.54 [-2.22, -0.86] |
| Jaafarpour, et al., 2008 | 5 | 5 | 54 | 12 | 4.2 | 54 | 1.2% | -1.51 [-1.93, -1.08] |
| Amer-Cuencu, et al., 2011 | 26.5 | 24.7 | 30 | 61.9 | 23.2 | 30 | 1.2% | -1.46 [-2.03, -0.88] |
| Sadala, et al., 2018 | 29.3 | 19.5 | 28 | 56.8 | 17.7 | 27 | 1.1% | -1.45 [-2.05, -0.86] |
| Park, et al., 2015 | 15 | 15 | 48 | 45 | 25 | 50 | 1.2% | -1.44 [-1.88, -0.99] |
| Ordog, 1987 | 30.4 | 2.8 | 25 | 54.8 | 2.5 | 25 | 1.1% | -1.35 [-1.97, -0.73] |
| Luchesa, et al., 2009 | 5 | 6 | 15 | 21 | 15.4 | 15 | 1.0% | -1.33 [-2.13, -0.53] |
| Cipriano, et al., 2008 | 20 | 7.4 | 23 | 30 | 7.4 | 22 | 1.1% | -1.33 [-1.98, -0.68] |
| Da Silva, et al., 2015 | 0.795 | 21 | 4 | 3.18 | 21 | 1.1% | -1.27 [-1.94, -0.60] | |
| Mahure, et al., 2017 | 36 | 21 | 15 | 58 | 12 | 15 | 1.0% | -1.25 [-2.04, -0.46] |
| Kayman-Kose, et al., 2014 (1) | 17.7 | 12.7 | 50 | 37.4 | 20.6 | 50 | 1.2% | -1.14 [-1.57, -0.72] |
| Lison, et al., 2017 | 23.2 | 31.4 | 46 | 53.1 | 19.9 | 46 | 1.2% | -1.13 [-1.57, -0.69] |
| Liu, et al., 1985 | 39.3 | 17.9 | 15 | 65.3 | 26.6 | 15 | 1.1% | -1.12 [-1.89, -0.34] |
| Cuschieri, et al., 1987 | 30 | 11.25 | 10 | 49 | 20.25 | 10 | 1.0% | -1.11 [-2.07, -0.15] |
| Emmler, et al., 2008 | 24 | 11.8 | 20 | 39 | 14.8 | 20 | 1.1% | -1.10 [-1.77, -0.43] |
| Abreu, et al., 2010 | 68 | 23 | 10 | 88 | 10 | 10 | 1.0% | -1.08 [-2.03, -0.13] |
| Chandra, et al., 2010 | 7 | 5.3 | 30 | 14.7 | 8.6 | 30 | 1.2% | -1.06 [-1.61, -0.52] |
| Pitangu, et al., 2014 | 17.2 | 21.9 | 11 | 38.8 | 20.8 | 10 | 1.0% | -0.97 [-1.89, -0.05] |
| Yilmaz, et al., 2019 | 7.3 | 9.8 | 26 | 20 | 15.7 | 26 | 1.2% | -0.96 [-1.53, -0.38] |
| Aminisarman, et al., 2020 | 26.6 | 5.4 | 30 | 31.2 | 4.8 | 30 | 1.2% | -0.89 [-1.42, -0.36] |
| Oncel, et al., 2002 | 24 | 13 | 25 | 39 | 20 | 25 | 1.2% | -0.88 [-1.46, -0.29] |
| Elboini, et al., 2020 | 41.7 | 19.2 | 23 | 61.2 | 25 | 18 | 1.1% | -0.87 [-1.52, -0.22] |
| Zakariaee, et al., 2019 | 31.8 | 20.4 | 40 | 47.5 | 16.5 | 40 | 1.2% | -0.84 [-1.30, -0.38] |
| Domaille & Reeves, 1997 | 30.33 | 8.14 | 31 | 47 | 28.14 | 29 | 1.2% | -0.81 [-1.33, -0.28] |
| Ficorelli, et al., 2012 | 39 | 8 | 23 | 45 | 7 | 23 | 1.1% | -0.78 [-1.39, -0.18] |
| Likar, et al. 2001 | 25.1 | 7.6 | 11 | 29.7 | 4.8 | 12 | 1.0% | -0.70 [-1.55, 0.14] |
| Warfield, et al., 1985 | 48.3 | 20.1 | 12 | 64.2 | 24.6 | 12 | 1.0% | -0.68 [-1.51, 0.14] |
| Fujii-Abe, et al., 2019 | 22.1 | 12.8 | 11 | 30.3 | 11.2 | 11 | 1.0% | -0.66 [-1.52, 0.21] |
| Bjers, et al., 2015 | 13 | 16 | 15 | 26 | 24 | 13 | 1.1% | -0.63 [-1.39, 0.14] |
| Bjers & Andersson, 2014 | 19.4 | 32.5 | 9 | 39.6 | 32 | 11 | 1.0% | -0.60 [-1.51, 0.30] |
| Sezen, et al., 2017 | 36.9 | 7.2 | 43 | 42 | 10.1 | 44 | 1.2% | -0.58 [-1.00, -0.15] |
| Gallie, et al., 2015 | 21 | 16 | 37 | 29 | 22 | 37 | 1.2% | -0.41 [-0.87, 0.05] |
| Ferreira, et al., 2011 | 18 | 18 | 15 | 25 | 18 | 15 | 1.1% | -0.38 [-1.10, 0.34] |
| Rakel & Frantz, 2003 (2) | 42 | 33.45 | 33 | 55 | 37.3 | 33 | 1.2% | -0.36 [-0.85, 0.12] |
| Hruby, et al., 2006 | 35 | 28.8 | 48 | 43.7 | 30.6 | 49 | 1.2% | -0.29 [-0.69, 0.11] |
| Robinson, et al., 2001 | 38.2 | 31.24 | 10 | 47.92 | 36.37 | 13 | 1.0% | -0.27 [-1.10, 0.56] |
| Hamza, et al., 1999 | 25 | 23 | 25 | 31 | 25 | 25 | 1.2% | -0.25 [-0.80, 0.31] |
| Cuschieri, et al., 1985 | 25 | 21.8 | 53 | 28 | 21.8 | 53 | 1.2% | -0.14 [-0.52, 0.24] |
| Forster, et al., 1994 | 9.8 | 28.1 | 15 | 13.7 | 31.9 | 15 | 1.1% | -0.13 [-0.84, 0.59] |
| Yilmazer, et al., 2012 | 54.6 | 32.1 | 33 | 57.5 | 30.5 | 32 | 1.2% | -0.09 [-0.58, 0.40] |
| Thomas, et al., 1988 | 33 | 31.1 | 131 | 35 | 33.8 | 144 | 1.3% | -0.06 [-0.30, 0.18] |
| Presser, et al., 2000 | 47 | 38.34 | 30 | 49 | 27.39 | 30 | 1.2% | -0.06 [-0.57, 0.45] |
| Tucker, et al., 2015 | 56 | 56 | 35 | 57 | 57 | 35 | 1.2% | -0.02 [-0.49, 0.45] |
| Lee, et al., 2015 | 55.6 | 9.2 | 18 | 54.4 | 12.9 | 18 | 1.1% | 0.10 [-0.55, 0.76] |
| Silva, et al., 2012 | 22.5 | 11.5 | 21 | 20 | 12.5 | 21 | 1.1% | 0.20 [-0.40, 0.81] |
| Beckwée, et al., 2018 | 39.2 | 25.1 | 25 | 30.6 | 23.2 | 28 | 1.2% | 0.35 [-0.19, 0.90] |
| Kayman-Kose, et al., 2014 (3) | 13.5 | 5.8 | 50 | 7.8 | 7 | 50 | 1.2% | 0.88 [0.47, 1.29] |
| Subtotal (95% CI) | 1667 | | | 1681 | | | 65.0% | -1.02 [-1.25, -0.80] |

Heterogeneity: Tau² = 0.64; Chi² = 493.78, df = 57 (P < 0.00001); I² = 88%

Test for overall effect: Z = 9.03 (P < 0.00001)

7.10.2 Chronic Pain

| | | | | | | | | |
|-----------------------------|-------|-------|-----|-------|-------|----|-------|------------------------|
| Barbarisi, et al., 2010 | 25.11 | 0.92 | 9 | 39 | 1.19 | 8 | 0.1% | -12.50 [-17.39, -7.61] |
| Hokenet, et al., 2019 | 22 | 12.49 | 39 | 72 | 18.7 | 39 | 1.1% | -3.11 [-3.78, -2.44] |
| Lauretti, et al., 2015 | 20 | 10 | 20 | 70 | 20 | 20 | 1.0% | -3.10 [-4.05, -2.15] |
| Ekim, et al., 2008 | 47.2 | 5.6 | 10 | 65.3 | 6.3 | 9 | 0.7% | -2.91 [-4.29, -1.54] |
| Dalley, et al., 2013 (4) | 40 | 4 | 41 | 47 | 4 | 41 | 1.2% | -1.73 [-2.24, -1.22] |
| Kibar, et al., 2020 | 21.2 | 12.2 | 31 | 47.6 | 19.6 | 30 | 1.2% | -1.60 [-2.18, -1.02] |
| Zhang, et al., 2020a | 17 | 3 | 10 | 31 | 12.6 | 10 | 0.9% | -1.46 [-2.48, -0.45] |
| De Oliveira, et al., 2012 | 30 | 16.4 | 5 | 54 | 13.6 | 5 | 0.7% | -1.44 [-2.92, 0.04] |
| Bi, et al., 2015 | 21.4 | 9.1 | 26 | 38.7 | 14.5 | 26 | 1.1% | -1.41 [-2.02, -0.80] |
| Topuz, et al., 2004 | 37.3 | 16.2 | 15 | 59.1 | 13.7 | 12 | 1.0% | -1.40 [-2.25, -0.54] |
| Celik, et al., 2013 | 38.8 | 25 | 17 | 67.7 | 14.2 | 16 | 1.1% | -1.38 [-2.14, -0.61] |
| Lauretti, et al., 2013 | 60 | 10 | 13 | 80 | 20 | 10 | 1.0% | -1.28 [-2.19, -0.36] |
| Suh, et al., 2015 | 18.7 | 7.46 | 24 | 30.7 | 17.67 | 23 | 1.1% | -0.88 [-1.48, -0.28] |
| Neighbours, et al., 1987 | 17.5 | 30.3 | 10 | 40.7 | 20.74 | 10 | 1.0% | -0.86 [-1.78, 0.07] |
| Vitali & Oleg, 2014 | 39.5 | 17 | 11 | 52.5 | 18.6 | 10 | 1.0% | -0.70 [-1.59, 0.19] |
| Biçili, et al., 2016 | 14.27 | 10.1 | 15 | 23.27 | 15.8 | 15 | 1.1% | -0.66 [-1.40, 0.08] |
| Shimoura, et al., 2019 | 5.1 | 8 | 25 | 11.4 | 10.9 | 25 | 1.2% | -0.65 [-1.22, -0.08] |
| Liu, et al., 2017 | 48.2 | 17.7 | 22 | 55.8 | 12.6 | 22 | 1.1% | -0.49 [-1.09, 0.11] |
| Grimmer, 1992 | 22 | 28 | 20 | 35 | 29 | 20 | 1.1% | -0.45 [-1.08, 0.18] |
| Dalley, et al., 2020 | 46 | 20 | 103 | 53 | 19.9 | 99 | 1.3% | -0.35 [-0.63, -0.07] |
| Warke, et al., 2004 | 28.25 | 36.5 | 5 | 40.33 | 19.4 | 3 | 0.7% | -0.33 [-1.78, 1.12] |
| Machin, et al., 1988 | 13.47 | 13.72 | 15 | 16.29 | 13.65 | 15 | 1.1% | -0.20 [-0.92, 0.52] |
| Moore & Shurman, 1997 (5) | 40.58 | 27.55 | 24 | 44.81 | 30.67 | 24 | 1.2% | -0.14 [-0.71, 0.42] |
| Shimoji, et al., 2007 | 38 | 15 | 9 | 40 | 20 | 8 | 1.0% | -0.11 [-1.06, 0.84] |
| Graff-Radford, et al., 1989 | 28.3 | 18.06 | 12 | 30.2 | 15.92 | 12 | 1.0% | -0.11 [-0.91, 0.89] |
| Sahin, et al., 2011 | 68.5 | 15.5 | 19 | 69.5 | 11.5 | 19 | 1.1% | -0.07 [-0.71, 0.56] |
| Ilhani, 2015 | 22.4 | 11.3 | 35 | 22.8 | 10.2 | 31 | 1.2% | -0.04 [-0.52, 0.45] |
| Bono, et al., 2015 | 80 | 20 | 54 | 80 | 20 | 54 | 1.2% | 0.00 [-0.38, 0.38] |
| Machado, et al., 2019 | 47 | 25 | 22 | 46 | 22 | 22 | 1.1% | 0.04 [-0.55, 0.63] |
| Atamaz, et al., 2012 | 54.7 | 24.1 | 37 | 50.4 | 20.3 | 37 | 1.2% | 0.19 [-0.27, 0.65] |
| Kofotolis, et al., 2008 | 22 | 4 | 23 | 20 | 4 | 21 | 1.1% | 0.49 [-0.11, 1.09] |
| Subtotal (95% CI) | 721 | | | 696 | | | 32.0% | -0.87 [-1.19, -0.55] |

Heterogeneity: Tau² = 0.72; Chi² = 9.83, df = 2 (P = 0.007); I² = 80%

Test for overall effect: Z = 1.01 (P = 0.31)

7.10.3 Not Reported

| | | | | | | | | |
|------------------------|-------|-------|----|-------|-------|----|------|----------------------|
| Cheing & Luk, 2005 | 17 | 17 | 10 | 46 | 20 | 9 | 0.9% | -1.50 [-2.55, -0.45] |
| Mansuri, et al., 2019 | 26.67 | 22.57 | 15 | 45.33 | 26.15 | 15 | 1.1% | -0.74 [-1.49, 0.00] |
| Siqueira, et al., 2019 | 2.92 | 6.6 | 13 | 0.7 | 1.6 | 14 | 1.1% | 0.48 [-0.31, 1.22] |
| Subtotal (95% CI) | 38 | | | 38 | | | 3.0% | -0.55 [-1.63, 0.52] |

Heterogeneity: Tau² = 0.72; Chi² = 9.83, df = 2 (P = 0.007); I² = 80%

Test for overall effect: Z = 10.48 (P < 0.00001)

Test for subgroup differences: Chi² = 1.16, df = 2 (P = 0.56), I² = 0%**Footnotes**

(1) Cesarian delivery sample

(2) Crossover

(3) Vaginal delivery sample

(4) Crossover

(5) Crossover

